The CAT’s meow: low-affinity CD19 CAR T cells show strong response with low toxicity in pediatric patients with ALL
September 18, 2019
Aiming to determine how the affinity of a CAR for its target impacts efficacy and toxicity associated with CAR T cell treatment, Ghorashian et al. developed a low-affinity single-chain variable fragment (scFv) targeting CD19, compared it directly to the high-affinity scFv in a currently approved CAR product in vitro and in mice, and...
September 11, 2019
Tumors with high neoantigen burdens tend to respond well to immunotherapy, but patients whose tumors express few or no neoantigens may not derive the same benefits. Enhancing the immunogenicity of tumors in a way that is clinically relevant and broadly translatable could be a way to enhance immunotherapy response rates. Building on previous...
Not redundant after all: improved T cell responses with dual PD-1 axis blockade in pancreatic cancer
September 4, 2019
Aiming to elucidate the role that neoantigens play in the response of pancreatic ductal adenocarcinoma (PDA) to immunotherapy, particularly in a subset of patients with PDA that is infiltrated by T cells, Burrack et al. developed a new mouse model expressing a neoantigen to study the fate of tumor-specific CD8+ T cells during...